ELESTAT® ophthalmic solution is indicated for the prevention of ocular itching associated with allergic conjunctivitis. ELESTAT® ophthalmic solution is contraindicated in those patients who have shown hypersensitivity to epinastine or to any of the other ingredients. Patients should be advised not to wear a contact lens if their eye is red. ELESTAT® ophthalmic solution should not be used to treat contact lens related irritation. The preservatives in ELESTAT®, benzalkonium chloride, may be absorbed by soft ontact lenses. Contact lenses should be removed prior to instillation of ELESTAT® ophthalmic solution and may be reinserted after 10 minutes following its administration. The most frequently reported ocular adverse events occurring in approximately 1% to 10% of patients were burning sensation in the eye, folliculosis, hyperemia, and pruritus. The most frequently reported nonocular adverse events were infection (cold symptoms and upper respiratory infections), seen in approximately 10% of patients, and headache, rhinitis, sinusitis, increased cough, and pharyngitis seen in approximately 1% to 3% of patients. Some of these events were similar to the underlying disease being studied. Please see prescribing information for ELESTAT®.

©2006 Inspire Pharmaceuticals, Inc., Durham, NC 27703 ® Marks owned by Allergan, Inc. Inspire and the Inspire logo are registered trademarks of Inspire Pharmaceuticals, Inc. ELESTAT® is licensed from Boehringer Ingelheim Pty. Ltd., Ingelheim, Germany.